Email updates

Keep up to date with the latest news and content from BMC Microbiology and BioMed Central.

Open Access Highly Accessed Research article

The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design

Hookang Im1, Miriam L Sharpe2, Ulrich Strych3, Milya Davlieva4 and Kurt L Krause2*

Author Affiliations

1 Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, Korea

2 Department of Biochemistry, University of Otago, Dunedin, New Zealand

3 Department of Biology and Biochemistry, University of Houston, Houston, TX, USA

4 Department of Biochemistry and Cell Biology, Rice University, Houston, TX, USA

For all author emails, please log on.

BMC Microbiology 2011, 11:116  doi:10.1186/1471-2180-11-116

Published: 25 May 2011

Abstract

Background

Streptococcus pneumoniae is a globally important pathogen. The Gram-positive diplococcus is a leading cause of pneumonia, otitis media, bacteremia, and meningitis, and antibiotic resistant strains have become increasingly common over recent years. Alanine racemase is a ubiquitous enzyme among bacteria and provides the essential cell wall precursor, D-alanine. Since it is absent in humans, this enzyme is an attractive target for the development of drugs against S. pneumoniae and other bacterial pathogens.

Results

Here we report the crystal structure of alanine racemase from S. pneumoniae (AlrSP). Crystals diffracted to a resolution of 2.0 Å and belong to the space group P3121 with the unit cell parameters a = b = 119.97 Å, c = 118.10 Å, α = β = 90° and γ = 120°. Structural comparisons show that AlrSP shares both an overall fold and key active site residues with other bacterial alanine racemases. The active site cavity is similar to other Gram positive alanine racemases, featuring a restricted but conserved entryway.

Conclusions

We have solved the structure of AlrSP, an essential step towards the development of an accurate pharmacophore model of the enzyme, and an important contribution towards our on-going alanine racemase structure-based drug design project. We have identified three regions on the enzyme that could be targeted for inhibitor design, the active site, the dimer interface, and the active site entryway.